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Purpose: Recently, we demonstrated that Trichostatin-A (TSA) inhibits transforming 
growth factor beta 1 (TGFβ1)-induced fibrosis (haze) in rabbit cornea in vivo. 
However, the molecular mechanism of this process is still unknown. This study tested 
the hypothesis that homeodomain transcription factors, TGIF1 and TGIF2 regulate 
anti-fibrotic effects of TSA in the cornea.  
 
Methods: An established in vitro model of corneal scarring was used. Primary 
corneal fibroblast (HSF) cultures generated from donor human corneas were exposed 
to TGFβ1 (1ng/ml), TSA (250 or 500nM), TGFβ1 (1ng/ml)+TSA (250/500nM) or 
vehicle. The quantification of alpha smooth muscle actin (αSMA), TGIF1 and TGIF2 
mRNA was performed with Real-time PCR and protein with immunoblotting and 
immunocytochemical techniques. Statistical analysis was performed using one way 
ANOVA. The p value < 0.05 was considered significant. 
 
Results: This study, for the first time, demonstrates that human corneal fibroblasts 
express TGIF and TGIF2 and play role in corneal fibrosis modulation. TGFβ1 
treatment to HSF significantly increased myofibroblasts (hallmark of corneal fibrosis) 
mRNA and protein levels of αSMA (myofibroblasts marker). TSA treatment showed 
significant decrease (60-75%; p<.05) in TGFβ1-induced fibrosis in human cornea in 
vitro. The anti-fibrotic effect of TSA was associated with a concurrent increase in 
TGIF and TGIF2 levels suggesting their role in the modulation of corneal fibrosis. 
 
Conclusions: The anti-fibrotic effects of TSA in the cornea involve TGIF1 and 
TGIF2 transcription factors.   
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